Thanks so much @Strawman for landing Jon and for running a great Q & A and interview. Jon seemed a lot more relaxed and informal than in previous interviews that I have seen.
There were some really important insights that were gained that I haven’t heard before today.
On a personal note thanks for asking all my questions – I was also the anonymous questioner (I hadn’t realised I needed to add my name on slido – woops)
I think a really key point was made between 20 min – 25 minutes in the interview.
Key insight:
1) If Phelan McDermid trial is successful in December Neuren will take the results straight to FDA to plan phase III. This was the first time I have heard Jon confirm the timeline and really adds to the excitement as a shareholder. This is a really important point as the momentum of this stock will just keep building – and likely keep adding value for share-holders.
Other important notes:
2) Note that safety has not been a concern and that is largely what an open label phase I study is about. Neuren has successfully jumped another drug safely from an animal model to a human trial. Acadia also had access to this data and $100 million was added to the deal to lock in NNZ2591 for Fragile X and Rett (I think this is a super important point). Efficacy will be interesting – fundamentally we are dealing with a similar functioning drug to Daybue but a more bioavailable model. I love to see Jon’s enthusiasm around this.
3) Interested parties (plural) for NNZ2591 for US rights – Neuren is certainly on the radar.
4) The lack of hiccups around insurance/ Medicaid and Medicare was reassuring and backed up by the stellar speed of uptake of Daybue.
5) Jon once again re-iterated that potential gene therapy would be an added benefit and unlikely to supplant Daybue – he has emphasised this before.
6) Jon’s surprise at the conservatism of analysis and broker models – so far they have been wrong on:
a. A the price of the drug
b. The speed of uptake
c. Suggesting to me the very conservative modelling out there by mainstream brokers
7) A real emphasis on the ORPHAN drug model – I personally was really pleased to hear this. There is a lot of scuttlebutt about Alzheimers or Autism I personally think these kind of large scale studies are much more difficult to run and less likely to produce definitive end points. I am glad they are sticking with what they know.
8) 4 Indications are more than enough to build an enduring and financially very worthwhile business.
9) His glowing comments about ACADIA are consistent – yes while they might go it alone it is also possible that ACADIA and NEUREN will get rolled up and bought as a package.
@Scoonie agree diarrhoea issue has been a prominent issue on forum discussions however there is a lot of optimism around creative solutions families are coming up with if willing to get through the initial teething issues. Another point to concentrate on as Jon has commented that NNZ2591 is unlikely to have these issues due to the smaller doses needed in the drug.
Thank you once again. Where else can you so easily get access to CEOs as a retail investor – other than Strawman?